American Century Companies Inc. Decreases Holdings in Exelixis, Inc. (NASDAQ:EXEL)

American Century Companies Inc. cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 440,004 shares of the biotechnology company’s stock after selling 1,848 shares during the quarter. American Century Companies Inc. owned 0.15% of Exelixis worth $9,887,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Fisher Asset Management LLC raised its stake in shares of Exelixis by 232.6% during the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 728 shares in the last quarter. Rise Advisors LLC purchased a new position in shares of Exelixis during the first quarter worth approximately $28,000. Park Place Capital Corp purchased a new position in shares of Exelixis in the second quarter worth $45,000. GAMMA Investing LLC increased its stake in shares of Exelixis by 107.9% in the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,041 shares during the period. Finally, EntryPoint Capital LLC increased its stake in shares of Exelixis by 537.2% in the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,746 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on EXEL. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Tuesday, July 30th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $27.00 target price on shares of Exelixis in a research note on Wednesday, August 7th. JMP Securities reaffirmed a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Friday. UBS Group began coverage on shares of Exelixis in a research note on Thursday. They issued a “neutral” rating and a $30.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research note on Wednesday, September 18th. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.67.

Insider Activity

In other news, EVP Dana Aftab sold 95,000 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the sale, the executive vice president now owns 520,990 shares in the company, valued at approximately $13,024,750. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Jeffrey Hessekiel sold 20,000 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $25.79, for a total value of $515,800.00. Following the transaction, the executive vice president now owns 630,325 shares in the company, valued at approximately $16,256,081.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Dana Aftab sold 95,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the completion of the transaction, the executive vice president now owns 520,990 shares in the company, valued at approximately $13,024,750. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 302,858 shares of company stock worth $7,980,629. Corporate insiders own 2.85% of the company’s stock.

Exelixis Trading Down 1.5 %

Shares of EXEL stock opened at $26.42 on Monday. Exelixis, Inc. has a 12 month low of $18.64 and a 12 month high of $27.83. The stock has a market cap of $8.01 billion, a PE ratio of 41.28, a price-to-earnings-growth ratio of 0.58 and a beta of 0.54. The company’s fifty day moving average price is $25.20 and its 200-day moving average price is $23.35.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The firm had revenue of $637.18 million for the quarter, compared to analysts’ expectations of $468.21 million. On average, sell-side analysts forecast that Exelixis, Inc. will post 1.54 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.